Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 52

1.

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry.

Du Z, Weinhold N, Song GC, Rand KA, Van Den Berg DJ, Hwang AE, Sheng X, Hom V, Ailawadhi S, Nooka AK, Singhal S, Pawlish K, Peters ES, Bock C, Mohrbacher A, Stram A, Berndt SI, Blot WJ, Casey G, Stevens VL, Kittles R, Goodman PJ, Diver WR, Hennis A, Nemesure B, Klein EA, Rybicki BA, Stanford JL, Witte JS, Signorello L, John EM, Bernstein L, Stroup AM, Stephens OW, Zangari M, Van Rhee F, Olshan A, Zheng W, Hu JJ, Ziegler R, Nyante SJ, Ingles SA, Press MF, Carpten JD, Chanock SJ, Mehta J, Colditz GA, Wolf J, Martin TG, Tomasson M, Fiala MA, Terebelo H, Janakiraman N, Kolonel L, Anderson KC, Le Marchand L, Auclair D, Chiu BC, Ziv E, Stram D, Vij R, Bernal-Mizrachi L, Morgan GJ, Zonder JA, Huff CA, Lonial S, Orlowski RZ, Conti DV, Haiman CA, Cozen W.

Blood Adv. 2020 Jan 14;4(1):181-190. doi: 10.1182/bloodadvances.2019000491.

2.

Interdependence of hypoxia and β-adrenergic receptor signaling in pulmonary arterial hypertension.

Stephens OR, Weiss K, Frimel M, Rose JA, Sun Y, Asosingh K, Farha S, Highland KB, Prasad SVN, Erzurum SC.

Am J Physiol Lung Cell Mol Physiol. 2019 Sep 1;317(3):L369-L380. doi: 10.1152/ajplung.00015.2019. Epub 2019 Jun 26.

PMID:
31242023
3.

Author Correction: Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N; PRACTICAL consortium, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2019 Jan 10;10(1):213. doi: 10.1038/s41467-018-08107-8.

4.

Genetic correlation between multiple myeloma and chronic lymphocytic leukaemia provides evidence for shared aetiology.

Went M, Sud A, Speedy H, Sunter NJ, Försti A, Law PJ, Johnson DC, Mirabella F, Holroyd A, Li N, Orlando G, Weinhold N, van Duin M, Chen B, Mitchell JS, Mansouri L, Juliusson G, Smedby KE, Jayne S, Majid A, Dearden C, Allsup DJ, Bailey JR, Pratt G, Pepper C, Fegan C, Rosenquist R, Kuiper R, Stephens OW, Bertsch U, Broderick P, Einsele H, Gregory WM, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Hansson M, Goldschmidt H, Dyer MJS, Kaiser M, Sonneveld P, Morgan GJ, Hemminki K, Nilsson B, Catovsky D, Allan JM, Houlston RS.

Blood Cancer J. 2018 Dec 21;9(1):1. doi: 10.1038/s41408-018-0162-8.

5.

Identification of multiple risk loci and regulatory mechanisms influencing susceptibility to multiple myeloma.

Went M, Sud A, Försti A, Halvarsson BM, Weinhold N, Kimber S, van Duin M, Thorleifsson G, Holroyd A, Johnson DC, Li N, Orlando G, Law PJ, Ali M, Chen B, Mitchell JS, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Bandapalli OR, Einsele H, Gregory WA, Gullberg U, Hillengass J, Hoffmann P, Jackson GH, Jöckel KH, Johnsson E, Kristinsson SY, Mellqvist UH, Nahi H, Easton D, Pharoah P, Dunning A, Peto J, Canzian F, Swerdlow A, Eeles RA, Kote-Jarai Z, Muir K, Pashayan N, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Thomsen H, Turesson I, Vangsted A, Andersen NF, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Goldschmidt H, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Hemminki K, Nilsson B, Houlston RS; PRACTICAL consortium.

Nat Commun. 2018 Sep 13;9(1):3707. doi: 10.1038/s41467-018-04989-w. Erratum in: Nat Commun. 2019 Jan 10;10(1):213.

6.

Detection of Cross-Sample Contamination in Multiple Myeloma Samples and Sequencing Data.

Stephens OW, Meißner T, Weinhold N.

Methods Mol Biol. 2018;1792:147-155. doi: 10.1007/978-1-4939-7865-6_10.

PMID:
29797257
7.

The multiple myeloma risk allele at 5q15 lowers ELL2 expression and increases ribosomal gene expression.

Ali M, Ajore R, Wihlborg AK, Niroula A, Swaminathan B, Johnsson E, Stephens OW, Morgan G, Meissner T, Turesson I, Goldschmidt H, Mellqvist UH, Gullberg U, Hansson M, Hemminki K, Nahi H, Waage A, Weinhold N, Nilsson B.

Nat Commun. 2018 Apr 25;9(1):1649. doi: 10.1038/s41467-018-04082-2.

8.

Kinase domain activation through gene rearrangement in multiple myeloma.

Morgan GJ, He J, Tytarenko R, Patel P, Stephens OW, Zhong S, Deshpande S, Bauer M, Weinhold N, Schinke C, Rasche L, Bailey M, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Zangari M, van Rhee F, Mughal T, Davies FE, Walker BA.

Leukemia. 2018 Nov;32(11):2435-2444. doi: 10.1038/s41375-018-0108-y. Epub 2018 Mar 23.

9.

Host genetic susceptibility to Clostridium difficile infections in patients undergoing autologous stem cell transplantation: a genome-wide association study.

Apewokin S, Lee JY, Goodwin JA, McKelvey KD, Stephens OW, Zhou D, Coleman EA.

Support Care Cancer. 2018 Sep;26(9):3127-3134. doi: 10.1007/s00520-018-4173-6. Epub 2018 Mar 28.

PMID:
29594489
10.

Spatial genomic heterogeneity in multiple myeloma revealed by multi-region sequencing.

Rasche L, Chavan SS, Stephens OW, Patel PH, Tytarenko R, Ashby C, Bauer M, Stein C, Deshpande S, Wardell C, Buzder T, Molnar G, Zangari M, van Rhee F, Thanendrarajan S, Schinke C, Epstein J, Davies FE, Walker BA, Meissner T, Barlogie B, Morgan GJ, Weinhold N.

Nat Commun. 2017 Aug 16;8(1):268. doi: 10.1038/s41467-017-00296-y.

11.

Pulmonary arterial hypertension treatment with carvedilol for heart failure: a randomized controlled trial.

Farha S, Saygin D, Park MM, Cheong HI, Asosingh K, Comhair SA, Stephens OR, Roach EC, Sharp J, Highland KB, DiFilippo FP, Neumann DR, Tang WHW, Erzurum SC.

JCI Insight. 2017 Aug 17;2(16). pii: 95240. doi: 10.1172/jci.insight.95240. eCollection 2017 Aug 17.

12.

Assessing the effect of obesity-related traits on multiple myeloma using a Mendelian randomisation approach.

Went M, Sud A, Law PJ, Johnson DC, Weinhold N, Försti A, van Duin M, Mitchell JS, Chen B, Kuiper R, Stephens OW, Bertsch U, Campo C, Einsele H, Gregory WM, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Lenive O, Nickel J, Nöthen MM, da Silva Filho MI, Thomsen H, Walker BA, Broyl A, Davies FE, Langer C, Hansson M, Kaiser M, Sonneveld P, Goldschmidt H, Hemminki K, Nilsson B, Morgan GJ, Houlston RS.

Blood Cancer J. 2017 Jun 16;7(6):e573. doi: 10.1038/bcj.2017.48. No abstract available.

13.

Bi-allelic inactivation is more prevalent at relapse in multiple myeloma, identifying RB1 as an independent prognostic marker.

Chavan SS, He J, Tytarenko R, Deshpande S, Patel P, Bailey M, Stein CK, Stephens O, Weinhold N, Petty N, Steward D, Rasche L, Bauer M, Ashby C, Peterson E, Ali S, Ross J, Miller VA, Stephens P, Thanendrarajan S, Schinke C, Zangari M, van Rhee F, Barlogie B, Mughal TI, Davies FE, Morgan GJ, Walker BA.

Blood Cancer J. 2017 Feb 24;7(2):e535. doi: 10.1038/bcj.2017.12.

14.

FDA Approval Summary: TAS-102.

Marcus L, Lemery SJ, Khasar S, Wearne E, Helms WS, Yuan W, He K, Cao X, Yu J, Zhao H, Wang Y, Stephens O, Englund E, Agarwal R, Keegan P, Pazdur R.

Clin Cancer Res. 2017 Jun 15;23(12):2924-2927. doi: 10.1158/1078-0432.CCR-16-2157. Epub 2017 Feb 17.

15.

Hypoxia sensing through β-adrenergic receptors.

Cheong HI, Asosingh K, Stephens OR, Queisser KA, Xu W, Willard B, Hu B, Dermawan JKT, Stark GR, Naga Prasad SV, Erzurum SC.

JCI Insight. 2016 Dec 22;1(21):e90240. doi: 10.1172/jci.insight.90240.

16.

FDA Approval: Alectinib for the Treatment of Metastatic, ALK-Positive Non-Small Cell Lung Cancer Following Crizotinib.

Larkins E, Blumenthal GM, Chen H, He K, Agarwal R, Gieser G, Stephens O, Zahalka E, Ringgold K, Helms W, Shord S, Yu J, Zhao H, Davis G, McKee AE, Keegan P, Pazdur R.

Clin Cancer Res. 2016 Nov 1;22(21):5171-5176. Epub 2016 Jul 13.

17.

Clonal selection and double-hit events involving tumor suppressor genes underlie relapse in myeloma.

Weinhold N, Ashby C, Rasche L, Chavan SS, Stein C, Stephens OW, Tytarenko R, Bauer MA, Meissner T, Deshpande S, Patel PH, Buzder T, Molnar G, Peterson EA, van Rhee F, Zangari M, Thanendrarajan S, Schinke C, Tian E, Epstein J, Barlogie B, Davies FE, Heuck CJ, Walker BA, Morgan GJ.

Blood. 2016 Sep 29;128(13):1735-44. doi: 10.1182/blood-2016-06-723007. Epub 2016 Aug 11.

18.

FDA Approval: Uridine Triacetate for the Treatment of Patients Following Fluorouracil or Capecitabine Overdose or Exhibiting Early-Onset Severe Toxicities Following Administration of These Drugs.

Ison G, Beaver JA, McGuinn WD Jr, Palmby TR, Dinin J, Charlab R, Marathe A, Jin R, Liu Q, Chen XH, Ysern X, Stephens O, Bai G, Wang Y, Dorff SE, Cheng J, Tang S, Sridhara R, Pierce W, McKee AE, Ibrahim A, Kim G, Pazdur R.

Clin Cancer Res. 2016 Sep 15;22(18):4545-9. doi: 10.1158/1078-0432.CCR-16-0638. Epub 2016 Jul 11. Review.

19.

Genome-wide association study identifies multiple susceptibility loci for multiple myeloma.

Mitchell JS, Li N, Weinhold N, Försti A, Ali M, van Duin M, Thorleifsson G, Johnson DC, Chen B, Halvarsson BM, Gudbjartsson DF, Kuiper R, Stephens OW, Bertsch U, Broderick P, Campo C, Einsele H, Gregory WA, Gullberg U, Henrion M, Hillengass J, Hoffmann P, Jackson GH, Johnsson E, Jöud M, Kristinsson SY, Lenhoff S, Lenive O, Mellqvist UH, Migliorini G, Nahi H, Nelander S, Nickel J, Nöthen MM, Rafnar T, Ross FM, da Silva Filho MI, Swaminathan B, Thomsen H, Turesson I, Vangsted A, Vogel U, Waage A, Walker BA, Wihlborg AK, Broyl A, Davies FE, Thorsteinsdottir U, Langer C, Hansson M, Kaiser M, Sonneveld P, Stefansson K, Morgan GJ, Goldschmidt H, Hemminki K, Nilsson B, Houlston RS.

Nat Commun. 2016 Jul 1;7:12050. doi: 10.1038/ncomms12050.

20.

Genome-wide association study identifies variation at 6q25.1 associated with survival in multiple myeloma.

Johnson DC, Weinhold N, Mitchell JS, Chen B, Kaiser M, Begum DB, Hillengass J, Bertsch U, Gregory WA, Cairns D, Jackson GH, Försti A, Nickel J, Hoffmann P, Nöethen MM, Stephens OW, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ.

Nat Commun. 2016 Jan 8;7:10290. doi: 10.1038/ncomms10290.

21.

Genetic factors influencing the risk of multiple myeloma bone disease.

Johnson DC, Weinhold N, Mitchell J, Chen B, Stephens OW, Försti A, Nickel J, Kaiser M, Gregory WA, Cairns D, Jackson GH, Hoffmann P, Noethen MM, Hillengass J, Bertsch U, Barlogie B, Davis FE, Hemminki K, Goldschmidt H, Houlston RS, Morgan GJ.

Leukemia. 2016 Apr;30(4):883-8. doi: 10.1038/leu.2015.342. Epub 2015 Dec 16.

22.

A common genetic variant in 19q13·3 is associated with outcome of multiple myeloma patients treated with Total Therapy 2 and 3.

Erickson SW, Stephens OW, Chavan SS, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Br J Haematol. 2016 Sep;174(6):991-3. doi: 10.1111/bjh.13830. Epub 2015 Nov 16. No abstract available.

PMID:
26568154
23.

Common genetic variants in 11q13.3 and 9q22.33 are associated with molecular subgroups of multiple myeloma.

Erickson SW, Stephens OW, Chavan SS, Tian E, Epstein J, Barlogie B, Heuck CJ, Vangsted AJ.

Leukemia. 2015 Dec;29(12):2418-21. doi: 10.1038/leu.2015.238. Epub 2015 Aug 26. No abstract available.

24.

Contribution of Clostridium difficile infection to the development of lower gastrointestinal adverse events during autologous stem cell transplantation.

Apewokin S, Goodwin JA, Lee JY, Erickson SW, Sanathkumar N, Raj VR, Zhou D, McKelvey KD, Stephens O, Coleman EA.

Transpl Infect Dis. 2015 Aug;17(4):566-73. doi: 10.1111/tid.12403. Epub 2015 Jun 27.

PMID:
25988273
25.

Genome-wide scan identifies variant in 2q12.3 associated with risk for multiple myeloma.

Erickson SW, Raj VR, Stephens OW, Dhakal I, Chavan SS, Sanathkumar N, Coleman EA, Lee JY, Goodwin JA, Apewokin S, Zhou D, Epstein J, Heuck CJ, Vangsted AJ.

Blood. 2014 Sep 18;124(12):2001-3. doi: 10.1182/blood-2014-07-586701. No abstract available.

PMID:
25237182
26.

GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis.

Coleman EA, Lee JY, Erickson SW, Goodwin JA, Sanathkumar N, Raj VR, Zhou D, McKelvey KD, Apewokin S, Stephens O, Enderlin CA, Vangsted AJ, Reed PJ, Anaissie EJ.

Support Care Cancer. 2015 Mar;23(3):841-9. doi: 10.1007/s00520-014-2406-x. Epub 2014 Sep 14.

27.

CD2-associated protein (CD2AP) enhances casitas B lineage lymphoma-3/c (Cbl-3/c)-mediated Ret isoform-specific ubiquitination and degradation via its amino-terminal Src homology 3 domains.

Calco GN, Stephens OR, Donahue LM, Tsui CC, Pierchala BA.

J Biol Chem. 2014 Mar 14;289(11):7307-19. doi: 10.1074/jbc.M113.537878. Epub 2014 Jan 14.

28.

Interleukin-6 receptor polymorphism is prevalent in HIV-negative Castleman Disease and is associated with increased soluble interleukin-6 receptor levels.

Stone K, Woods E, Szmania SM, Stephens OW, Garg TK, Barlogie B, Shaughnessy JD Jr, Hall B, Reddy M, Hoering A, Hansen E, van Rhee F.

PLoS One. 2013;8(1):e54610. doi: 10.1371/journal.pone.0054610. Epub 2013 Jan 23.

29.

Prediction of cytogenetic abnormalities with gene expression profiles.

Zhou Y, Zhang Q, Stephens O, Heuck CJ, Tian E, Sawyer JR, Cartron-Mizeracki MA, Qu P, Keller J, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2012 May 24;119(21):e148-50. doi: 10.1182/blood-2011-10-388702. Epub 2012 Apr 10.

30.

An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification.

Stephens OW, Zhang Q, Qu P, Zhou Y, Chavan S, Tian E, Williams DR, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2012 Jan 12;119(2):503-12. doi: 10.1182/blood-2011-07-367052. Epub 2011 Nov 9.

31.

Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3.

Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B.

Blood. 2011 Sep 29;118(13):3512-24. doi: 10.1182/blood-2010-12-328252. Epub 2011 May 31.

32.

High-risk myeloma is associated with global elevation of miRNAs and overexpression of EIF2C2/AGO2.

Zhou Y, Chen L, Barlogie B, Stephens O, Wu X, Williams DR, Cartron MA, van Rhee F, Nair B, Waheed S, Pineda-Roman M, Alsayed Y, Anaissie E, Shaughnessy JD Jr.

Proc Natl Acad Sci U S A. 2010 Apr 27;107(17):7904-9. doi: 10.1073/pnas.0908441107. Epub 2010 Apr 12.

33.

Genetic polymorphisms of EPHX1, Gsk3beta, TNFSF8 and myeloma cell DKK-1 expression linked to bone disease in myeloma.

Durie BG, Van Ness B, Ramos C, Stephens O, Haznadar M, Hoering A, Haessler J, Katz MS, Mundy GR, Kyle RA, Morgan GJ, Crowley J, Barlogie B, Shaughnessy J Jr.

Leukemia. 2009 Oct;23(10):1913-9. doi: 10.1038/leu.2009.129. Epub 2009 Aug 6.

34.

Identification of a beta3-peptide HIV fusion inhibitor with improved potency in live cells.

Bautista AD, Stephens OM, Wang L, Domaoal RA, Anderson KS, Schepartz A.

Bioorg Med Chem Lett. 2009 Jul 15;19(14):3736-8. doi: 10.1016/j.bmcl.2009.05.032. Epub 2009 May 15.

35.

Ellipticine derivative NSC 338258 represents a potential new antineoplastic agent for the treatment of multiple myeloma.

Tian E, Landowski TH, Stephens OW, Yaccoby S, Barlogie B, Shaughnessy JD Jr.

Mol Cancer Ther. 2008 Mar;7(3):500-9. doi: 10.1158/1535-7163.MCT-07-0524. Epub 2008 Mar 4.

36.

Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma.

Qiang YW, Chen Y, Stephens O, Brown N, Chen B, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2008 Jul 1;112(1):196-207. doi: 10.1182/blood-2008-01-132134. Epub 2008 Feb 27.

37.

Frequent engagement of the classical and alternative NF-kappaB pathways by diverse genetic abnormalities in multiple myeloma.

Annunziata CM, Davis RE, Demchenko Y, Bellamy W, Gabrea A, Zhan F, Lenz G, Hanamura I, Wright G, Xiao W, Dave S, Hurt EM, Tan B, Zhao H, Stephens O, Santra M, Williams DR, Dang L, Barlogie B, Shaughnessy JD Jr, Kuehl WM, Staudt LM.

Cancer Cell. 2007 Aug;12(2):115-30.

38.

The oxidative stress response regulates DKK1 expression through the JNK signaling cascade in multiple myeloma plasma cells.

Colla S, Zhan F, Xiong W, Wu X, Xu H, Stephens O, Yaccoby S, Epstein J, Barlogie B, Shaughnessy JD Jr.

Blood. 2007 May 15;109(10):4470-7. Epub 2007 Jan 25.

39.

Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation.

Clines GA, Mohammad KS, Bao Y, Stephens OW, Suva LJ, Shaughnessy JD Jr, Fox JW, Chirgwin JM, Guise TA.

Mol Endocrinol. 2007 Feb;21(2):486-98. Epub 2006 Oct 26.

40.

High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients.

Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD Jr, Brennan C, Depinho RA.

Cancer Cell. 2006 Apr;9(4):313-25.

41.

Inhibiting HIV fusion with a beta-peptide foldamer.

Stephens OM, Kim S, Welch BD, Hodsdon ME, Kay MS, Schepartz A.

J Am Chem Soc. 2005 Sep 28;127(38):13126-7.

42.

beta-Peptides as inhibitors of protein-protein interactions.

Kritzer JA, Stephens OM, Guarracino DA, Reznik SK, Schepartz A.

Bioorg Med Chem. 2005 Jan 3;13(1):11-6.

43.

The binding selectivity of ADAR2's dsRBMs contributes to RNA-editing selectivity.

Stephens OM, Haudenschild BL, Beal PA.

Chem Biol. 2004 Sep;11(9):1239-50.

44.

Recognition of double-stranded RNA by proteins and small molecules.

Carlson CB, Stephens OM, Beal PA.

Biopolymers. 2003 Sep;70(1):86-102. Review.

PMID:
12925995
45.

Synthesis and analysis of RNA containing 6-trifluoromethylpurine ribonucleoside.

Véliz EA, Stephens OM, Beal PA.

Org Lett. 2001 Sep 20;3(19):2969-72.

PMID:
11554820
46.

Conformational changes that occur during an RNA-editing adenosine deamination reaction.

Yi-Brunozzi HY, Stephens OM, Beal PA.

J Biol Chem. 2001 Oct 12;276(41):37827-33. Epub 2001 Jul 30.

47.

Analysis of the RNA-editing reaction of ADAR2 with structural and fluorescent analogues of the GluR-B R/G editing site.

Stephens OM, Yi-Brunozzi HY, Beal PA.

Biochemistry. 2000 Oct 10;39(40):12243-51.

PMID:
11015203
48.

Mutagenicity of para-nitroso-dimethyl- and diethyl-anilines.

Goodall CM, Moore CM, Stephens OB.

Xenobiotica. 1986 Jun;16(6):587-93.

PMID:
3529653
49.
50.

Correlation of human bladder tumor recurrence with changes in clonogenicity of urothelial cells.

Noronha RF, Goodall CM, Beagley KW, Stephens OB, Horne L.

Cancer. 1985 Oct 1;56(7):1574-7.

PMID:
4027894

Supplemental Content

Loading ...
Support Center